title: Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.
abstract: BACKGROUND
  This multicenter, double-blind, randomized, controlled study conducted in China examined the efficacy and safety of olanzapine versus lithium in the treatment of patients with bipolar manic/mixed episodes.
  
  
  METHODS
  Patients with bipolar manic or mixed episode (DSM-IV criteria) and Young Mania Rating Scale (YMRS) score> or =20 at screening received olanzapine (5-20 mg/day, n=69) or lithium carbonate (600-1800 mg/day, n=71) for 4 weeks. The primary outcome was mean change from baseline in Clinical Global Impressions-Bipolar Version Overall Severity of Illness (CGI-BP) score. Secondary efficacy measures included YMRS, Brief Psychiatric Rating Scale (BPRS), and Montgomery-Asberg Depression Rating Scale (MADRS) scores. Safety was also assessed.
  
  
  RESULTS
  A significantly greater mean change was observed in olanzapine versus lithium patients in CGI-BP (Overall Severity) (P=0.009), YMRS (P=0.013), BPRS (P=0.032), and CGI-BP (Severity of Mania) (P=0.012) scores. More olanzapine than lithium patients experienced at least one adverse event possibly related to study drug (P=0.038). More olanzapine patients had a clinically significant weight increase (> or =7% of baseline weight) compared to lithium patients (P=0.009). More olanzapine patients completed the study than lithium patients, although this difference was not statistically significant (olz, 91.3%; lith, 78.9%; P=0.057).
  
  
  CONCLUSIONS
  No placebo arm was included; however both treatments have previously been reported to be more effective than placebo.
  
  
  CONCLUSIONS
  These results suggest that olanzapine has superior efficacy to lithium in the acute treatment of patients with bipolar mania over a 4-week period. However, adverse events were experienced by a greater number of olanzapine patients than lithium patients.
authors.affiliation: Shanghai Mental Health Center, Shanghai, People's Republic of China.
authors.forename: Gu
authors.initials: G
authors.lastname: Niufan
authors.forename: Mauricio
authors.initials: M
authors.lastname: Tohen
authors.forename: Ang
authors.initials: A
authors.lastname: Qiuqing
authors.forename: Yang
authors.initials: Y
authors.lastname: Fude
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Pope
authors.forename: Heather
authors.initials: H
authors.lastname: McElroy
authors.forename: Li
authors.initials: L
authors.lastname: Ming
authors.forename: Wang
authors.initials: W
authors.lastname: Gaohua
authors.forename: Zhang
authors.initials: Z
authors.lastname: Xinbao
authors.forename: Li
authors.initials: L
authors.lastname: Huichun
authors.forename: Shu
authors.initials: S
authors.lastname: Liang
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000453:epidemiology; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000150:complications / Q000188:drug therapy*; D010054:Brief Psychiatric Rating Scale; D003866:Depressive Disorder / Q000150:complications / Q000175:diagnosis; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D016651:Lithium Carbonate / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009765:Obesity / Q000139:chemically induced / Q000453:epidemiology; D000077152:Olanzapine; D011569:Psychiatric Status Rating Scales; D012720:Severity of Illness Index; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D016651:Lithium Carbonate; D000077152:Olanzapine